Fresh analysis suggests that individuals who discontinue popular GLP-1 drugs like Mounjaro or Wegovy tend to recover reduced body mass at a significantly accelerated pace than those who end traditional lifestyle regimens.
Findings released in a leading medical journal points out that while obese individuals can lose a large proportion of their body weight while undergoing treatment, the mass returns at an estimated rate of 0.8 kg per month after stopping.
"Individuals buying these drugs should be informed of the risk of quick rebound weight gain when the treatment concludes," cautioned expert Dr. Susan Jebb.
Such speed of regain suggests a reversion to original mass in about 18 months.
Analyzing Therapies
The study, which examined 37 of trials involving thousands of patients, contrasted the outcomes of the injectable medications with conventional dieting.
The team emphasize that individuals who shed pounds through dieting typically see a slower creep back—approximately 100 grams monthly—once they finish.
Explaining the Rapid Rebound
Doctors propose the way of the drugs is key to understanding the accelerated weight return.
These medications copy a natural hormone called GLP-1, which moderates feelings of fullness.
"Long-term administration of the hormone levels several times higher than normal may cause the system to produce less of its own natural hormone, and could diminish responsiveness to its actions," noted Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this GLP-1 'fix' leads to hunger is uncontrolled, making binge eating a significant risk."
A Lifelong Disease?
Health authorities suggest the injections for people with weight-linked medical conditions, accompanied by prescribed diet and exercise modifications.
Professionals say that, considering the likelihood of relapse, the treatment should be considered ongoing.
This perspective is reinforced by pharmaceutical companies, who state that the findings "emphasize the long-term character of excess weight," akin to managing diseases like hypertension.
Patient Testimonies
Users who have stopped the jabs describe a sudden resurgence of cravings.
"I experienced something activating and you become starving," described an individual.
This challenge is exacerbated if patients have not adopted permanent lifestyle or habit modifications during therapy.
Widespread Adoption
Survey data show that millions of people in the UK have tried these injections in the past year, with interest remaining high.
- Use is greater among females than men.
- The middle-aged demographic shows the greatest usage rates.
- A large proportion obtain the drugs through private healthcare rather than the NHS.
Finally, researchers stress that while the jabs are potent tools for shedding pounds, they are not a permanent fix and lasting health benefits relies on combined behavioural support.
